PURPOSE: To assess risk factors of patients with oropharyngeal squamous cell carcinoma in the Munich area of Southern Germany in relation to human papillomavirus (HPV) association of the tumors. To demonstrate differences in tumor characteristics and their impact on adjuvant treatment. METHODS: Between November 2010 and July 2013, patients were prospectively interviewed for risk factors before they underwent surgical resection of their tumors. HPV association was evaluated by p16 immunohistochemistry; tumor characteristics and type of adjuvant treatment were recorded. Follow-up data were collected after a median follow-up of 12.1 month. RESULTS: In contrast to many recent studies, we could not detect any difference in overall age and age at sexual debut between p16-positive and p16-negative patients. P16-negative patients are characterized by a more intensive tobacco and alcohol use, a more abusive way of consumption, less nonoral and less oral sex partners. P16-positive patients had a significantly higher risk of lymph node metastases, but nevertheless a significant lower risk to recur or to die. No difference in the incidence of synchronous second primary tumors was seen. P16-positive patients generally received a more aggressive adjuvant treatment because of more frequently involved lymph nodes. CONCLUSION: Lifestyle risk factors such as smoking, drinking, and sexual habits were independent from age, but showed marked differences between the p16-positive and p16-negative group. Since p16-positive patients were treated more aggressively, it is not possible to distinguish whether the better outcome of HPV-positive patients is a result of less aggressive cancers or more aggressive treatment. With regard to the ongoing debate about treatment deintensification, we should keep in mind that the survival of HPV-positive cancer patients is not 100 %.
PURPOSE: To assess risk factors of patients with oropharyngeal squamous cell carcinoma in the Munich area of Southern Germany in relation to human papillomavirus (HPV) association of the tumors. To demonstrate differences in tumor characteristics and their impact on adjuvant treatment. METHODS: Between November 2010 and July 2013, patients were prospectively interviewed for risk factors before they underwent surgical resection of their tumors. HPV association was evaluated by p16 immunohistochemistry; tumor characteristics and type of adjuvant treatment were recorded. Follow-up data were collected after a median follow-up of 12.1 month. RESULTS: In contrast to many recent studies, we could not detect any difference in overall age and age at sexual debut between p16-positive and p16-negative patients. P16-negative patients are characterized by a more intensive tobacco and alcohol use, a more abusive way of consumption, less nonoral and less oral sex partners. P16-positive patients had a significantly higher risk of lymph node metastases, but nevertheless a significant lower risk to recur or to die. No difference in the incidence of synchronous second primary tumors was seen. P16-positive patients generally received a more aggressive adjuvant treatment because of more frequently involved lymph nodes. CONCLUSION: Lifestyle risk factors such as smoking, drinking, and sexual habits were independent from age, but showed marked differences between the p16-positive and p16-negative group. Since p16-positive patients were treated more aggressively, it is not possible to distinguish whether the better outcome of HPV-positivepatients is a result of less aggressive cancers or more aggressive treatment. With regard to the ongoing debate about treatment deintensification, we should keep in mind that the survival of HPV-positive cancerpatients is not 100 %.
Authors: J P Klussmann; S J Weissenborn; U Wieland; V Dries; J Kolligs; M Jungehuelsing; H E Eckel; H P Dienes; H J Pfister; P G Fuchs Journal: Cancer Date: 2001-12-01 Impact factor: 6.860
Authors: Drew C Brotherston; Ian Poon; Tuyen Le; Martin Leung; Alex Kiss; Jolie Ringash; Judith Balogh; Justin Lee; James R Wright Journal: Head Neck Date: 2012-03-20 Impact factor: 3.147
Authors: Brian O'Sullivan; Shao Hui Huang; Lillian L Siu; John Waldron; Helen Zhao; Bayardo Perez-Ordonez; Ilan Weinreb; John Kim; Jolie Ringash; Andrew Bayley; Laura A Dawson; Andrew Hope; John Cho; Jonathan Irish; Ralph Gilbert; Patrick Gullane; Angela Hui; Fei-Fei Liu; Eric Chen; Wei Xu Journal: J Clin Oncol Date: 2013-01-07 Impact factor: 44.544
Authors: P Sinha; W T Thorstad; B Nussenbaum; B H Haughey; D R Adkins; D Kallogjeri; J S Lewis Journal: Oral Oncol Date: 2013-11-06 Impact factor: 5.337
Authors: Pamela Zengel; Gerald Assmann; Martin Mollenhauer; Andreas Jung; Karl Sotlar; Thomas Kirchner; Stephan Ihrler Journal: Virchows Arch Date: 2012-08-02 Impact factor: 4.064
Authors: William Strober; Sachie Shishido; Burton Wood; James S Lewis; Krystle Kuhs; Robert L Ferris; Daniel L Faden Journal: Oral Oncol Date: 2019-11-22 Impact factor: 5.337
Authors: Katelyn Stepan; Ethan Craig; Scott Andrew Skillington; Brian C Deutsch; Stephanie Chen; Nneoma S Wamkpah; Craig A Bollig; Dorina Kallogjeri; Wade L Thorstad; Sidharth V Puram; Patrik Pipkorn; Ryan S Jackson Journal: Head Neck Date: 2022-02-17 Impact factor: 3.821
Authors: Chrystiano de C Ferreira; Rozany Dufloth; Ana C de Carvalho; Rui M Reis; Iara Santana; Raiany S Carvalho; Ricardo R Gama Journal: PLoS One Date: 2021-06-17 Impact factor: 3.240